ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 143 filers reported holding ASCENDIS PHARMA A/S in Q1 2019. The put-call ratio across all filers is 0.49 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $2,548,000 | +39.5% | 15,276 | +29.1% | 0.19% | +5.1% |
| Q3 2020 | $1,826,000 | -14.7% | 11,832 | -18.2% | 0.18% | -6.3% |
| Q2 2020 | $2,140,000 | +43.2% | 14,467 | +9.1% | 0.19% | +82.7% |
| Q1 2020 | $1,494,000 | -32.8% | 13,263 | -17.0% | 0.10% | +2.0% |
| Q4 2019 | $2,223,000 | +67.8% | 15,976 | +16.1% | 0.10% | +59.4% |
| Q3 2019 | $1,325,000 | -37.6% | 13,758 | -25.4% | 0.06% | +52.4% |
| Q2 2019 | $2,124,000 | +10.9% | 18,446 | +13.3% | 0.04% | +13.5% |
| Q1 2019 | $1,915,000 | +77.3% | 16,274 | -5.6% | 0.04% | +60.9% |
| Q4 2018 | $1,080,000 | +28.9% | 17,245 | +45.7% | 0.02% | +64.3% |
| Q3 2018 | $838,000 | – | 11,833 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |